Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug

Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial

Fineline Cube Mar 31, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn...

Company Drug

Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels

Fineline Cube Mar 31, 2026

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced FDA marketing approval for Ponlimsi, its biosimilar...

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with...

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026

AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an...

Medical Device

Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety

Fineline Cube Mar 31, 2026

Roche AG (SWX: ROG, OTCMKTS: RHHBY) has announced the commercial launch of its cobas MPX-E...

Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Fineline Cube Mar 31, 2026

China’s National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)’s Exdensur (depemokimab)...

Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Fineline Cube Mar 31, 2026

Kexing Biopharma (SHA: 688136) announced it has received approval from the U.S. Food and Drug...

Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026

Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi’an-based developer of bifunctional and multi-functional peptide therapeutics,...

Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026

China’s National Medical Products Administration (NMPA) has announced the review and approval of the “Working...

Company

Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib

Fineline Cube Mar 31, 2026

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results,...

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications

Fineline Cube Mar 31, 2026

China’s National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for...

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo...

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026

The Beijing State-owned Capital E-town CBC Industrial Investment Fund Partnership Enterprise, China’s largest specialized healthcare...

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026

Insilico Medicine (HKG: 3696), a pioneer in generative artificial intelligence (AI)-driven drug discovery, announced a...

Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data

Fineline Cube Mar 30, 2026

AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Tezspire®...

Company Medical Device

Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine

Fineline Cube Mar 30, 2026

Medtronic plc (NYSE: MDT) announced it has received U.S. Food and Drug Administration (FDA) marketing...

Company Medical Device

Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System

Fineline Cube Mar 30, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful...

Company Drug

Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults

Fineline Cube Mar 30, 2026

Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II...

Posts pagination

1 … 75 76 77 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.